Biomarkers for Ventilator-associated Pneumonia
ConditionPneumonia, Ventilator-Associated
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRegion Skane
About this trial
The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.
Eligibility criteria
Qualifiers
Admission to an intensive care unit
Intubation within last 24 hours
Anticipated mechanical ventilation of at least 48 hours
Disqualifiers
FiO2 above 70% or PEEP above 15
Severe coagulopathy (spontaneous PK(INR) >1.8 or thrombocytes <50). Prophylaxis treatment dose of LMWH or factor Xa inhibitors/NOAC is not an exclusion criteria. If higher doses of these substances are administered, the responsible clinician should be consulted before sample collection.
Ongoing infection of the lungs at admission to the ICU.
Severely elevated or instable intracranial pressure.
Trial design
Treatments tested in this trial
- Heparin-binding protein
- Interleukin-26
- Microbiome
- Bacterial transcriptome
- Proteome
Treatment groups
1,000 Participants
are divided into 3 treatment groupsSponsors and collaborators
Region Skane
Lead sponsor
Lund University
Collaborator
Source ClinicalTrials.gov